GlaxoSmithKline has temporarily shut down its manufacturing plant in Zebulon, North Carolina after Legionnella bacteria was found in a stand-alone cooling tower during routine inspection.
GlaxoSmithKline has temporarily shut down its manufacturing plant in Zebulon, North Carolina on August 11, 2015 after Legionnella bacteria was found in a stand-alone cooling tower during routine inspection. The bacteria causes Legionnaire’s disease, a deadly form of pneumonia. Staff at the Zebulon site have been sent home and told not to come in until the problem was resolved.
Testing of the plant is conducted every three months, said GSK spokeswoman, Jenni Brewer Ligday. She told the press that the company is investigating the situation. There is currently no reports of anyone contracting Legionnaire’s disease or that any products made at the plant were contaminated.
According to GSK, the tower does not come in contact with any with products manufactured at the plant. The company is, nonetheless, taking precautionary measures and trying to gather more information on whether any of its products have been affected.
In an Aug. 12 statement, the company reported that it closed the building because the cooling towers are needed to maintain proper temperature and humidity in the facility. GSK expects to resume operations in 72 hours following cleaning and disinfection.
A public health alert was not warranted, said city and state officials, and that no threat was posed to city drinking water, but tests are being conducted as a precaution, according to local newspapers, the Charlotte Observer.
Elsewhere in the Bronx region of New York, an outbreak of Legionnaires' disease has caused 12 deaths. At least 113 people have been infected since July 2015. In response, New York City's Department of Health has ordered the inspection and cleaning of all cooling towers.
Source: Reuters, New York Times
Editor's note: Updated Aug. 13, 2015 to add GSK statement.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.